Table 1.
Baseline demographic and lifestyle characteristics of patients in the CorEvitas Psoriasis Registry with eligible biologic initiations
| Total patients included (N = 2580) | |
|---|---|
| Demographic characteristicsa | |
| Age (years) | |
| Mean (SD) | 52.0 (13.2) |
| Median (IQRb) | 53.0 (43.0, 61.0) |
| Sex, n (%) | |
| Male | 1234 (47.8) |
| Female | 1346 (52.2) |
| Race, n (%) | |
| white | 2017 (78.2) |
| Black | 79 (3.1) |
| Asianc | 186 (7.2) |
| Hispanic | 194 (7.5) |
| Other/unknown | 104 (4.0) |
| Health insurance (n = 2393), n (%) | |
| Private (vs. non-private) | 1721 (71.9) |
| Education (n = 2573), n (%) | |
| Any college (vs. no college) | 1725 (67.0) |
| Employment, n (%) | |
| Not full-time | 1130 (43.8) |
| Full-time | 1450 (56.2) |
| Lifestyle characteristics | |
| Smoking status (n = 2559), n (%) | |
| Never smoked | 1181 (46.2) |
| Former/current smoker | 1378 (53.8) |
| Alcohol use (n = 2425), n (%) | |
| ≤ 1 drink per day | 1512 (62.4) |
| > 1 drink per day | 913 (37.6) |
| BMI, n (%) | |
| Underweight/normal (< 25 kg/m2) | 379 (14.7) |
| Overweight (25– < 30 kg/m2) | 745 (28.9) |
| Class 1 obesity (30– < 35 kg/m2) | 635 (24.6) |
| ≥ Class 2 obesity (≥ 35.0 kg/m2) | 821 (31.8) |
| History of concomitant diseasesd, n (%) | |
| 0 | 1877 (72.8) |
| 1 | 581 (22.5) |
| ≥ 2 | 122 (4.7) |
BMI body mass index, COPD chronic obstructive pulmonary disease, IQR interquartile range, SD standard deviation, TIA transient ischemic attack
aSample sizes may differ because of missing data and denominators are specified only when missing data were present
bInterquartile ranges (IQRs) are presented as the first and third quartiles
cThe specific ethnicity or nationality cannot be specified as the patient demographic data come from a registry source (CorEvitas Psoriasis Registry), which does not provide this level of detailed information
dThe total number of the following conditions: congestive heart failure, peripheral vascular disease, cerebrovascular disease (captured as stroke or TIA), COPD, peptic ulcer disease, diabetes mellitus, lymphoma, and solid tumor cancer (excluding non-melanoma skin cancer)